Dascena

Dascena is a machine learning diagnostic company that has developed algorithms designed to enable early detection and prediction of complex medical conditions. The company's flagship InSight algorithm utilizes patient vital sign data to predict the onset of sepsis, a life-threatening complication of infection. Clinical studies have demonstrated InSight's ability to reduce patient mortality by 39.5%, readmission rates by 22.7%, and hospital length of stay by 32.3%. Dascena has also developed Previse, an algorithm that can predict acute kidney injury (AKI) over 48 hours before symptom onset with 84% accuracy. In March 2022, the company received a grant from the National Institutes of Health (NIH) to evaluate the efficacy of its HindSight algorithm in predicting sepsis while adapting to site-specific data analysis workflows to reduce alert fatigue. The US Food and Drug Administration (FDA) awarded Breakthrough Device Designation to Previse in July 2020, recognizing its potential to provide early intervention for AKI.